Form 4 Tracker
Xenon Pharmaceuticals Inc.
XENE

22 insider filings · Latest: Oct 15, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Sep 30, 2026Oct 1 1:20 PMThomas Patrick KellyChief Financial Officer
Purchase
15,000$37.32$559.7K15,000(D)

View →

Sep 30, 2026Oct 1 1:19 PMIan MortimerDirector, PRESIDENT & CEO
Purchase
30,000$37.38$1.1M49,923(D)

View →

Aug 28, 2026Sep 1 1:59 AMChristopher John KenneyChief Medical Officer
Sale
7,068$60.25$425.8K2(D)

View →

Aug 28, 2026Aug 28 8:25 PMCHRISTOPHER KENNEY
Proposed Sale
7,068$61.93$437.7K—

View →

Aug 11, 2026Aug 13 8:33 PMSteven GannonDirector
Sale
10,000$64.06$640.6K1,870(D)

View →

Aug 11, 2026Aug 13 8:30 PMSTEVEN GANNON
Proposed Sale
10,000$64.06$640.6K—

View →

Jun 5, 2026Jun 9 1:19 AMGary PatouDirector
Sale
1,322$53.14$70.3K24,896(D)

View →

Jun 5, 2026Jun 9 1:19 AMGillian CannonDirector
Sale
1,190$53.14$63.2K1,455(D)

View →

Jun 5, 2026Jun 5 8:32 PMGILLIAN CANNON
Proposed Sale
1,190$52.99$63.1K—

View →

Jun 5, 2026Jun 5 8:32 PMGARY PATOU
Proposed Sale
1,322$52.99$70.1K—

View →

Mar 13, 2026Mar 14 12:16 AMChristopher John KenneyChief Medical Officer
Sale
1,410$55.23$77.9K7,069(D)

View →

Mar 13, 2026Mar 14 12:16 AMAndrea DifabioChief Legal Officer
Sale
1,342$55.23$74.1K7,301(D)

View →

Mar 13, 2026Mar 14 12:16 AMIan MortimerDirector, PRESIDENT & CEO
Sale
7,308$55.23$403.6K19,923(D)

View →

Mar 13, 2026Mar 13 11:51 PMCHRISTOPHER JOHN KENNEY
Proposed Sale
1,410$55.22$77.9K—

View →

Mar 13, 2026Mar 13 11:50 PMANDREA DIFABIO
Proposed Sale
1,342$55.23$74.1K—

View →

Mar 13, 2026Mar 13 11:49 PMIAN MORTIMER
Proposed Sale
7,308$55.22$403.6K—

View →

Mar 10, 2026Mar 11 11:21 PMChristopher John KenneyChief Medical Officer
Sale
2,771$60.11$166.6K4,729(D)

View →

Mar 10, 2026Mar 11 11:20 PMAndrea DifabioChief Legal Officer
Sale
2,607$60.11$156.7K4,893(D)

View →

Mar 10, 2026Mar 11 11:20 PMIan MortimerDirector, PRESIDENT & CEO
Sale
11,269$60.11$677.4K14,731(D)

View →

Mar 9, 2026Mar 11 11:20 PMIan MortimerDirector, PRESIDENT & CEO
Sale
270,000$60.33$16.3M6,000(D)

View →

Page 1 of 2

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Oct 15, 2026Oct 17 12:22 AMThomas Patrick KellyChief Financial Officer
Option Exercise
7,500—22,500(D)

View →

Sep 1, 2026Sep 4 12:26 AMDawn SvoronosDirector
Option Exercise
5,144$8.150(D)

View →

Jun 3, 2026Jun 4 1:04 AMGary PatouDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:04 AMGary PatouDirector
Option Exercise
2,645—0(D)

View →

Jun 3, 2026Jun 4 1:04 AMPatrick MachadoDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:04 AMPatrick MachadoDirector
Option Exercise
2,645—0(D)

View →

Jun 3, 2026Jun 4 1:04 AMJustin D. GoverDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:04 AMJustin D. GoverDirector
Option Exercise
2,645—0(D)

View →

Jun 3, 2026Jun 4 1:04 AMElizabeth A. GarofaloDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:04 AMElizabeth A. GarofaloDirector
Option Exercise
2,645—0(D)

View →

Jun 3, 2026Jun 4 1:04 AMSteven GannonDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:04 AMSteven GannonDirector
Option Exercise
2,645—0(D)

View →

Jun 3, 2026Jun 4 1:03 AMGillian CannonDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:03 AMGillian CannonDirector
Option Exercise
2,645—0(D)

View →

Jun 3, 2026Jun 4 1:03 AMDawn SvoronosDirector
Grant/Award
12,100$53.461,593(D)

View →

Jun 1, 2026Jun 4 1:03 AMDawn SvoronosDirector
Option Exercise
2,645—0(D)

View →

May 12, 2026May 14 1:40 AMSteven GannonDirector
Option Exercise
3,500$7.380(D)

View →

Mar 12, 2026Mar 14 12:16 AMChristopher John KenneyChief Medical Officer
Option Exercise
3,750—11,250(D)

View →

Mar 12, 2026Mar 14 12:16 AMAndrea DifabioChief Legal Officer
Option Exercise
3,750—11,250(D)

View →

Mar 12, 2026Mar 14 12:16 AMIan MortimerDirector, PRESIDENT & CEO
Option Exercise
12,500—37,500(D)

View →

Page 1 of 2

Next →